The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.